



a nominated partner site of



## THE PEOPLE



Mads H. Clausen




Luca Larai



Faranak Nami



## THE PROJECTS

### Medicinal chemistry prodrug development




### Identification of new autophagy inhibitors and their targets

#### Phenotypic screening



Target identification



## THE EQUIPMENT

Modern labs for synthetic and analytical chemistry, NMR (2 x 400, 600, 2 x 800 MHz), 3 x GC(MS), 3 x HPLC, 3 x UPLC-MS(MS), 2 x prep HPLC (with PDA/ELS/MS detection), microwave synthesizer, parallel synthesis carousels and reaction blocks, automated peptide and oligonucleotide synthesizers, reactor for photochemical reactions, autoclaves, H-cube, IR, spectrophotometers (UV-vis, fluorescent, CD), MALDI-TOF, Q-TOF, CombiFlash/Grace purifiers.

## THE MEDCHEM

Oncology, inflammation, infectious and metabolic disease. FBDD (Fragment Based Drug Design) and SBDD (Structure based Drug Design), synthesis of privileged and novel sp<sup>3</sup>-rich scaffolds, development of new synthetic methodologies, prodrug and analogue synthesis, focused library synthesis, multiparameter library optimization, virtual screening/computational chemistry/QSAR analysis, scaffold hopping. ADME profiling: Solubility, LogP/D, Caco-2, PAMPA, Microsomal stability, toxicity. Binding kinetics and fragment-based screening (NMR, ITC, TSA), X-Ray.

## THE OUTPUT

1. *J. Med. Chem.* 2018, 61, 3503
2. *Eur. J. Med. Chem.* 2018, 156, 738
3. *Angew. Chem.* 2017, 56, 2145
4. *Angew. Chem.* 2017, 56, 8153
5. *Chem. Sci.* 2018, 9, 3014

DK-OPENSREEN  
national infrastructure for chemical  
biology, four university partners

Spin-outs:  
GlycoSpot  
ROS Therapeutics  
IDYN Genomics



## THE FUTURE

Expansion of compound collection and medchem personnel

DTU Chemistry  
Kemitorvet 207, DK-2800 Kgs. Lyngby

**DK-OPENSREEN**

